Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma
Vanaja Konduri, Sujith K. Joseph, Tiara T. Byrd, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 592
Open Access | Times Cited: 21

Showing 21 citing articles:

Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept
Wenyu Luo, Ti Wen, Xiujuan Qu
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 24
Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies
Daniel B. Goodman, Camillia S. Azimi, Kendall Kearns, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 670
Open Access | Times Cited: 55
Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress
Hendrik Setia Budi, Firdaus Nuri Ahmad, Harun Achmad, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 47
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
Jianping Li, Zhiwen Xiao, Donghui Wang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 28
The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer
Haoyu Tang, Yizhi Cao, Yiwei Zhou, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 8
Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy
Jaitip Tipanee, Ermira Samara‐Kuko, Thierry Gevaert, et al.
Molecular Therapy (2022) Vol. 30, Iss. 10, pp. 3155-3175
Open Access | Times Cited: 37
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
Kexin Ai, Bowen Liu, Xiaomei Chen, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 7
CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer
Wei Ye, Tingting Xu, Chong Li, et al.
Cancer Immunology Research (2023) Vol. 11, Iss. 3, pp. 306-319
Open Access | Times Cited: 11
Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies
Dongdong Sun, Yijie Hu, Xin Li, et al.
International Immunopharmacology (2024) Vol. 144, pp. 113392-113392
Closed Access | Times Cited: 4
Unlocking the potential of chimeric antigen receptor T cell engineering immunotherapy: Long road to achieve precise targeted therapy for hepatobiliary pancreatic cancers
Hongli Gao, Lianyue Qu, Mu Li, et al.
International Journal of Biological Macromolecules (2025) Vol. 297, pp. 139829-139829
Closed Access
High tumor CD161 expression predicts a survival advantage and marks a Th1-skewed microenvironment
Briana A. Burns, Manju Chandra, Vanaja Konduri, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Poor clinical outcomes and immunoevasive contexture in CD161+CD8+T cells barren human pancreatic cancer
Qiangda Chen, Hanlin Yin, Zhenlai Jiang, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e008694-e008694
Open Access | Times Cited: 3
Immunostimulatory multi-interfacial bimetallic phosphide nanoparticles as photo-enhanced cascade nanozyme for cancer therapy
Xingru Zhao, Shuncheng Yao, Xingyi Wan, et al.
Applied Materials Today (2021) Vol. 25, pp. 101255-101255
Closed Access | Times Cited: 18
Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma
Hannah Pook, Siim Pauklin
Cancers (2021) Vol. 13, Iss. 19, pp. 4834-4834
Open Access | Times Cited: 7
Pooled screening of CAR T cells identifies non-native signaling domains for next-generation immunotherapies
Daniel B. Goodman, Camillia S. Azimi, Kendall Kearns, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 5
Bimetallic phosphidethe nanoparticles as photo-enhanced nanozymes for synergistic cancer immunotherapy
Xingru Zhao
Cancer Insight (2024) Vol. 3, Iss. 3, pp. 1-10
Open Access
The mechanisms of B-cell acute lymphoblastic leukemia relapsing following chimeric antigen receptor-T cell therapy; the plausible future strategies
Masoud Karimi‐Googheri, Mazaher Gholipourmalekabadi, Zahra Madjd, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access
Quantification of CAR T cell performance against acute myeloid leukemia using Bayesian inference
Saumil Shah, Jan Mueller, Michael Raatz, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Improved CAR T therapy for PDAC
Iain Dickson
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 7, pp. 456-456
Closed Access | Times Cited: 2
Transcriptomic Approaches in Studies on and Applications of Chimeric Antigen Receptor T Cells
Karolina Pierzynowska, Lidia Gaffke, Jan Maciej Zaucha, et al.
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1107-1107
Open Access
Construction of a novel signature based on immune-related lncRNA to identify high and low risk pancreatic adenocarcinoma patients
Na Li, Jionghuang Chen, Weihua Yu, et al.
BMC Gastroenterology (2023) Vol. 23, Iss. 1
Open Access
Page 1

Scroll to top